Kisspeptin is strictly for laboratory research and is commonly employed in the following investigational areas:

Hypothalamic-Pituitary-Gonadal (HPG) Axis Regulation

Kisspeptin is the standard control reagent for stimulating the release of GnRH in neuroendocrine models. Researchers utilize it to map the neural circuitry controlling puberty onset and reproductive feedback loops, specifically examining its stimulation of the HPG axis upon central or peripheral administration.

Oncology and Metastasis Inhibition

Referred to as “metastin,” Kisspeptin is heavily researched for its anti-metastatic properties. It is used to study the inhibition of cell migration and invasion in trophoblasts and cancer cell lines. Recent applications include its development as a radiopharmaceutical conjugate (DOTA-kisspeptin-10) for pan-tumor imaging and therapy.

Neuroprotection and Toxicology

In neurodegenerative research, Kisspeptin-10 is applied to cell models to assess its protective effects. Studies utilizing differentiated SH-SY5Y cells investigate the peptide’s ability to rescue cholinergic neurons from alpha-synuclein-induced toxicity, a key marker in Parkinson’s disease pathology.

Cardiovascular Remodeling and Hemodynamics

Kisspeptin is used to investigate tissue structure and vascular health. Research models involving cerebral aneurysms use the peptide to study the downregulation of Egr-1 expression as a preventative mechanism. Additionally, it is employed to measure collagen content increases in the myocardium mediated by focal adhesion kinase (FAK) activity.

Pathway / Mechanistic Context

The primary mechanism of action for Kisspeptin in research settings is the activation of the GPR54 receptor.

• Receptor Binding: Kisspeptin-10 binds to GPR54, inducing a conformational change that couples to Gq/11 proteins.
• Intracellular Cascade: This activation stimulates Phospholipase C (PLC), resulting in the hydrolysis of PIP2 into IP3 and DAG.
• Calcium Flux: IP3 triggers the release of intracellular calcium stores, which is the critical signal for GnRH exocytosis in hypothalamic neurons and the modulation of cytoskeletal dynamics in migratory cells.

Preclinical Research Summary

Published preclinical literature documents investigations of Kisspeptin across multiple experimental models for pathway characterization and endpoint measurement:

• Invasion Inhibition: In vitro studies demonstrate that Kisspeptin-10 inhibits the migration of HTR8SVneo cells via a receptor-GSK3 beta-FAK feedback loop, confirming its role as a physiological invasion inhibitor.
• Cerebral Vascular Health: Research indicates that Kisspeptin-10 prevents the development of cerebral aneurysms by reducing the expression of the transcription factor Egr-1 and suppressing macrophage-mediated inflammation.
• Myocardial Fibrosis: Experimental data shows that Kisspeptin-10 increases collagen content in the myocardium, suggesting a role in cardiac tissue remodeling through the activation of focal adhesion kinase.
• Radiopharmaceuticals: Synthesis and characterization studies have validated DOTA-kisspeptin-10 as a potential Gallium-68 or Lutetium-177 labeled tracer for tumor imaging, leveraging the peptide’s high affinity for receptors overexpressed in certain cancers.

Form & Analytical Testing

This material is produced via robust solid-phase peptide synthesis and supplied as a lyophilized (freeze-dried) powder.

• Lyophilization: Removes water content under vacuum to maintain peptide integrity and extend shelf-life.
• Identity Verification: Each lot undergoes Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the ≥99% purity standard required for reproducible research data.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Reeve, R., Marjanovic-Painter, B., Kleynhans, J., Driver, C., Millar, R., Ebenhan, T., Zeevaart, J., & Sathekge, M. (2025). Synthesis and characterisation of DOTA‐kisspeptin‐10 as a potential gallium‐68/lutetium‐177 pan‐tumour radiopharmaceutical. Journal of Neuroendocrinology, 37. https://doi.org/10.1111/jne.13487.
• Roseweir, A., Millar, R., et al. (2012). Kisspeptin-10 inhibits cell migration in vitro via a receptor-GSK3 beta-FAK feedback loop in HTR8SVneo cells. Placenta, 33 5, 408-15. https://doi.org/10.1016/j.placenta.2012.02.001.
• Song, Y., Ni, Y., Ding, L., Zhu, N., & Zhao, M. (2020). The KiSS-1/GPR54 system: Essential roles in physiological homeostasis and cancer biology. Genes & Diseases, 9, 28 – 40. https://doi.org/10.1016/j.gendis.2020.07.008.
• Smith, K., Murphy, K., et al. (2004). Central and Peripheral Administration of Kisspeptin‐10 Stimulates the Hypothalamic‐Pituitary‐Gonadal Axis. Journal of Neuroendocrinology, 16. https://doi.org/10.1111/J.1365-2826.2004.01240.X.
• Ghaffari‐Tabrizi, N., et al. (2004). Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. Journal of Cell Science, 117, 1319 – 1328. https://doi.org/10.1242/jcs.00971.
• Liufu, X. (2025). Kisspeptin-10 Prevents the Development of Cerebral Aneurysms by Reducing the Expression of Egr-1. CNS neuroscience & therapeutics, 31 5, e70413. https://doi.org/10.1111/cns.70413.
• Ahemad, N., Simon, C., Bhuvanendran, S., Soga, T., & Parhar, I. (2022). Kisspeptin-10 Rescues Cholinergic Differentiated SHSY-5Y Cells from α-Synuclein-Induced Toxicity In Vitro. International Journal of Molecular Sciences, 23. https://doi.org/10.3390/ijms23095193.
• Drobnik, J., Gałdyszyńska, M., Radwańska, P., & Piera, L. (2023). Kisspeptin-10 increases collagen content in the myocardium by focal adhesion kinase activity. Scientific Reports, 13. https://doi.org/10.1038/s41598-023-47224-3.
• Lebedev, A., Bychkov, E., Shabanov, P., & Pyurveev, S. (2025). Pharmacological analysis of the role of kisspeptin-10 in reinforcing mechanisms. Research Results in Pharmacology. https://doi.org/10.18413/rrpharmacology.11.544.

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.